Wyeth Studies Indicate Aprela Is SMARTer Choice Than Evista In Osteoporosis
Executive Summary
Phase III data showing Wyeth's Aprela is associated with a significant increase in bone mineral density in menopausal women compared to raloxifene may provide an opportunity to assert superiority in labeling over Lilly's Evista